| Objective:CD 105 is also named as Endoglin(EDG),which is a proliferation-associated endothelial cell membrane antigen, and highly expresses on the proliferating endothelial cells.It can modulate the reaction of endothelial cell to transforming growth factor-beta(TGF- beta),participate in angiogenesis.It plays a certain role in the courses of wound healing,embryonic developing,inflammatory reacting,as well as the growth of epithelial of tumor blood vessels.Serum S-CD105 is found highly in primary breast cancer,and maybe decrease to normal level in a short time after operation.Our investigation mainly detectes the levels of serum S-CD105 of patients with postoperative recurrent and metastatic breast cancer by enzyme-linked immunosorbent assay(ELISA).And make comparison with serum CEA,CA15-3 of the patients in the corresponding period.We hope to find a new marker for diagnosing postoperative recurrent and metastatic breast cancer in the early time.Materials and Method:We randomly selected 50 postoperative recurrent and metastatic breast cancer patients who containing 36 with distant metastasis and 14 with local recurrence(including chest wall recurrence and ipsilateral regional lymph node metastasis).They were reinspection or rehospitalization in the Fourth Hospital of Hebei Medicial University during March 2007 to December 2008.We also selected 20 patients with breast benign disease(9 with fibroadenoma of breast,9 with adenopathies tumor of breast,2 with breast intraductal papilloma) and 15 healthy subjects as control.We detected the levels of serum S-CD105 of them by ELISA,and then analyzed the results.Meanwhile we measured the serum CEA,CA15-3 of the patients with postoperative recurrent and metastatic breast cancer in corresponding period by microparticle chemilumin-escence immunoassay,and made comparison with S-CD105.All statistical analysis were performed by SPSS 11.5.Results:1 The serum S-CD105 levels of the patients with postoperative distant metastasis breast cancer group,local recurrence group,breast benign disease group and healthy control group were 22.81ng/ml(3.30-38.10ng/ml),20.00ng/ml (3.57-36.65ng/ml),11.55ng/ml(0.99-22.20ng/ml) and 10.62ng/ ml(7.81-19.39ng/ml).respectively.There was significant difference among them(P=0.000).By further analysis,we found that there was significant difference among distant metastasis,benign disease and healthy control groups(P= 0.000). So as to local recurrence,benign disease and healthy control groups(P=0.014).But there was no difference between local recurrence and distant metastasis(P=0.342),the same to benign disease and healthy control group(P= 0.934).2 The postoperative recurrent and metastatic breast cancer patients could be divided into(-) group and(+) group according to the measured values of S-CD105 below or up the maximum value(19.39ng/ml)of healthy control group.According to the normal reference values(CEA < 5U/ml,CA15-3 < 30, respectively) given on the kit,it also could be divided into(-) group and(+) group.In addition,we defined it as(+) whenever CEA,CA15-3 or both of them was(+).The positive rate of serum S-CD105 of patients with postoperative recurrent and metastatic breast cancer was 72%.While compared with that of the corresponding period of serum CEA(42%) and CA15-3 (44%),there were significant differences(P=0.002,P=0.005, respectively).However,there was no difference when we compare it with the positive rate of combining test of CEA and CA15-3(66%)(P=0.517).In the further statistics,the positive rate would raise to 90%when we combined three of them.It would be much better than S-CD105 as a signal marker or combining test of CEA and CA15-3(P=0.022,P=0.004, respectively).3 The patients with postoperative recurrent and metastatic breast cancer could be divided into five groups by different recurrence or metastatic sites.7 with ipsilateral regional lymph node metastasis,7 with chest wall recurrence,15 with visceral metastasis,9 with osseous metastasis and 11 with osseous composites visceral metastasis.The levels of serum S-CD105 of them were 24.24 ng/ml(17.09-36.65),13.98ng/ml (3.57-31.14),24.80ng/ml(3.30-38.10ng/ml),22.72ng/ml(13.50 -29.53ng/ml) and 19.47ng/ml(13.04-31.81 ng/ml),respectively. There was no difference among them(P=0.065).It was found that the positive rate of S-CD105 was higher than CEA or CA15-3 as a signal marker(P=0.014,P=0.035,respectively) when we made statistical analysis according to the different recurrence or metastatic sites,but there was no difference with combining test of CEA and CA15-3(P=0.330).While there was no difference when we made diagnosis of ipsilateral regional lymph node metastasis,chest wall recurrence,osseous metastasis and osseous composites visceral metastasis(P>0.05, all).4 The value of serum S-CD105 of patients with postoperative recurrence and metastasis breast cancer had no relationship with pathological type(P=0.649),lymph node metastasis(P=0.611),ER(P=0.071),PR(P=0.331),HER-2(P= 0.623) and the menopausal status(P=0.952).Conclusion:1 The levels of serum S-CD105 of patients with postoperative recurrent or metastatic breast cancer are much higher than those of breast benign disease and healthy control.But there is no difference between local recurrence and distant metastasis,so as to breast benign disease group and healthy control.It indicates that the recurrent or metastatic cells are the source of serum S-CD105.2 The positive rate of serum S-CD105 of patients with postoperative recurrent and metastatic breast cancer is higher than CEA,CA15-3,respectively.But there is no difference when compared it to combining test of CEA and CA15-3.The positive rate will raise much higher when we detected all of them at the same time.Therefore,it indicates that serum S-CD105 can be a marker for monitoring postoperative recurrent and metastasis of breast cancer.3 There is no difference of serum S-CD105 of patients with postoperative recurrent and metastatic breast cancer among different recurrence and metastasis sites.It can be found that S-CD105 is better than CEA,CA15-3 as a signal marker when occerred visceral metastasis,but there is no difference when comparing to combining test of CEA and CA15-3.There is no difference when we made diagnosis of ipsilateral regional lymph node metastasis,chest wall recurrence,osseous metastasis and osseous composites visceral metastasis.4 The level of serum S-CD105 of patients with postoperative recurrent and metastatic breast cancer has no relationship with pathological type,axillary lymph node metastasis,ER,PR,HER-2 and the menopausal status. |
PDF Full Text Request